These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16467104)

  • 1. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
    Norenberg JP; Krenning BJ; Konings IR; Kusewitt DF; Nayak TK; Anderson TL; de Jong M; Garmestani K; Brechbiel MW; Kvols LK
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):897-903. PubMed ID: 16467104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
    De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
    Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
    Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
    Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
    Nayak TK; Norenberg JP; Anderson TL; Prossnitz ER; Stabin MG; Atcher RW
    Nucl Med Biol; 2007 Feb; 34(2):185-93. PubMed ID: 17307126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors.
    Ugur O; Kothari PJ; Finn RD; Zanzonico P; Ruan S; Guenther I; Maecke HR; Larson SM
    Nucl Med Biol; 2002 Feb; 29(2):147-57. PubMed ID: 11823119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
    J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
    Bloechl S; Beck R; Seidl C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7070s-7074s. PubMed ID: 16203804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
    Konijnenberg MW; Bijster M; Krenning EP; De Jong M
    J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
    de Jong M; Bakker WH; Krenning EP; Breeman WA; van der Pluijm ME; Bernard BF; Visser TJ; Jermann E; Béhé M; Powell P; Mäcke HR
    Eur J Nucl Med; 1997 Apr; 24(4):368-71. PubMed ID: 9096086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas.
    Merlo A; Hausmann O; Wasner M; Steiner P; Otte A; Jermann E; Freitag P; Reubi JC; Müller-Brand J; Gratzl O; Mäcke HR
    Clin Cancer Res; 1999 May; 5(5):1025-33. PubMed ID: 10353735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy.
    Beutler D; Avoledo P; Reubi JC; Mäcke HR; Müller-Brand J; Merlo A; Kühne T
    Cancer; 2005 Feb; 103(4):869-73. PubMed ID: 15641034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
    Nayak T; Norenberg J; Anderson T; Atcher R
    Cancer Biother Radiopharm; 2005 Feb; 20(1):52-7. PubMed ID: 15778581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
    Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
    Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
    J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas.
    Bodei L; Handkiewicz-Junak D; Grana C; Mazzetta C; Rocca P; Bartolomei M; Lopera Sierra M; Cremonesi M; Chinol M; Mäcke HR; Paganelli G
    Cancer Biother Radiopharm; 2004 Feb; 19(1):65-71. PubMed ID: 15068613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The inhibitory effect of (111)In-DTPA(0)-octreotide on intrahepatic tumor growth after partial hepatectomy.
    Slooter GD; Aalbers AG; Breeman WA; Hiemstra CA; Marquet RL; Krenning EP; van Eijck CH
    J Nucl Med; 2002 Dec; 43(12):1681-7. PubMed ID: 12468520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.
    de Jong M; Breeman WA; Bakker WH; Kooij PP; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt MA; Erion JL; Bugaj JE; Mäcke HR; Krenning EP
    Cancer Res; 1998 Feb; 58(3):437-41. PubMed ID: 9458086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model.
    Lewis JS; Lewis MR; Cutler PD; Srinivasan A; Schmidt MA; Schwarz SW; Morris MM; Miller JP; Anderson CJ
    Clin Cancer Res; 1999 Nov; 5(11):3608-16. PubMed ID: 10589778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.